Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents. Issue 7 (July 2022)

• Record Type: Journal Article
• Authors: Han, Jinhe; Lee, Myoung Kyu; Jang, Yejin; Cho, Won-Jea; Kim, Meeheyin
• Is Part Of: Drug discovery today. Volume 27:Issue 7(2022)
• Page Start: 1895
• Page End: 1912
• Publication Date: 2022-07
• Subjects: Cyclophilin A -- Antiviral -- Drug repurposing -- Cyclosporin A -- Debio-025; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2022.05.016
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: CypA is a proviral factor in HCV, CoV, HIV and HBV infections. CypA is an antiviral factor against influenza virus and rotavirus infections. CypA inhibitors are classified into derivatives of CsA or sanglifehrin A and micro-molecules. Abstract: Cyclophilin A (CypA) is linked to diverse human diseases including viral infections. With the worldwide emergence of severe acute respiratory coronavirus 2 (SARS-CoV-2), drug repurposing has been highlighted as a strategy with the potential to speed up antiviral development. Because CypA acts as a proviral component in hepatitis C virus, coronavirus and HIV, its inhibitors have been suggested as potential treatments for these infections. Here, we review the structure of cyclosporin A and sanglifehrin A analogs as well as synthetic micromolecules inhibiting CypA; and we discuss their broad-spectrum antiviral efficacy in the context of the virus lifecycle.